drug

ALN-HTT02

1 story · latest Oct 29, 2026

Follow ALN-HTT02. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Alnylam Pharmaceuticals

Timeline

Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's program

Oct 29Quarterly updateAlnylam Pharmaceuticals nucresiran

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.